# Medtronic plc Moat

Status: published. Policy: company-analysis-1.

Medtronic's proprietary devices, achieved regulatory clearances and long-lived implants support plausible intangible-asset and switching-cost advantages. The supplied passages do not establish durable competitive protection across its portfolio. Growth and committed purchases demonstrate demand, while procurement pressure and historical industry share shifts limit confidence in pricing discretion and resilience. Realized pricing cannot be isolated from the supplied results. MiniMed's completed separation also limits the relevance of historical consolidated performance to today's business.

## intangible_assets

Exclusive device technology and achieved regulatory clearances establish differentiated products and commercialization capabilities. Their ability to sustain an economic moat remains unproven.

Durability: BlueSync appears in both the 2024 and 2026 business disclosures, demonstrating continued deployment. However, the passages provide neither patent protection horizons nor sustained comparative clinical or market-share outcomes.

Risks: Patent expiry, competing technology, quality problems and procurement pressure require continuing innovation and regulatory execution. Historical industry share shifts show that incumbency can be disrupted.

Invalidation: The proposed advantage would weaken if equivalent competing products removed meaningful differentiation, regulatory or quality failures restricted commercialization, or successive launches failed to sustain demand.

Competitors: Not established
## switching_costs

Long-lived implanted devices and device-linked monitoring plausibly create continuity costs within an existing patient relationship. Noncancellable minimum-purchase contracts establish a bounded commitment, without proving portfolio-wide customer lock-in.

Durability: Implant duration supports continuity during treatment, and disclosed purchase commitments extend beyond one year. Replacement loyalty, interoperability restrictions and physician switching costs are not quantified.

Risks: Continuity for an implanted patient need not protect future hospital purchasing or replacement decisions. Competitive tenders, clinical evidence and safety issues can redirect new demand.

Invalidation: This hypothesis would be undermined by easy migration of monitoring or treatment to alternatives, weak replacement loyalty, or declining committed purchases alongside sustained losses of repeat demand.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm) · 2026-06-18
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm) · 2025-06-20
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm) · 2024-06-20
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm) · 2026-09-03
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm) · 2026-02-24
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/exhibit991-statementdatedo.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/exhibit991-statementdatedo.htm) · 2026-10-19
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/exhibit991-fy27q1earningsr.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/exhibit991-fy27q1earningsr.htm) · 2026-09-01
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026040034/exhibit991-fy26q4earningsr.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026040034/exhibit991-fy26q4earningsr.htm) · 2026-06-03
- [https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm](https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm) · 2026-08-17
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/mdt-20261015.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/mdt-20261015.htm) · 2026-10-19
- [https://www.sec.gov/Archives/edgar/data/1613103/000162828025048375/mdt-20251101.htm](https://www.sec.gov/Archives/edgar/data/1613103/000162828025048375/mdt-20251101.htm) · 2025-11-03

[JSON](https://beanvest.com/stock/mdt/moat.json)